knowledge -WSS

knowledge

author：hotspot 2025-09-29 18:18:40 - browse：2

Is biotech back from its downturn? Can Nvidia solve biology? And is it wise to do a deal on a party bus?

We cover all that and more this week on “The Readout LOUD,” STAT’s biotech podcast. Recording from the J.P. Morgan Healthcare Conference, we discuss how a spate of deals and some intermittent sunshine seem to have brightened the outlook for biotech at the outset of 2024. We also talk about the latest twist in the Sarepta Therapeutics saga, a ubiquitous dealmaker, and life on the party circuit.

For more on what we cover, here’s the news on Sarepta; here’s more on Nvidia; here’s the story on Centerview; here’s where you can find episodes of Color Code; here’s where you can subscribe to the First Opinion Podcast; and here’s where you can subscribe to our biotech newsletter, The Readout.

Be sure to sign up on Apple Podcasts, Spotify, Stitcher, TuneIn, or wherever you get your podcasts.

And if you have any feedback for us — topics to cover, guests to invite, vocal tics to cease — you can email [email protected].

Previous article： Cancer drug shortages should be causing more outrage
Next article： 3 trends to watch in health tech's hiring outlook for 2024

WSS

3 hurdles to bringing medical devices to the U.S. market

3 trends to watch in health tech's hiring outlook for 2024

Chronically ill young patients struggle to find fertility info

JPM 2024 Day 3: Biotech Updates from Verve, Roivant, etc

The FDA must approve intranasal treatments for anaphylaxis

CDC concerned about possible undetected monkeypox spread in U.K.

explore

knowledge

hotspot

Medicare details structure of new drug price negotiation program

Antibiotic resistance and the global rise in human conflict

Hepatitis C has a cure — but many Americans still lack access to it

Ahead of JPM, here's who's profiting most in health care

DIEP, the 'gold standard' of breast reconstruction, is under threat

The battle over the Brookhaven Landfill on Long Island

Jerome Adams on the need for new antivirals for Covid

Why we need to separate burnout from moral injury in health care

Jerome Adams on the need for new antivirals for Covid

The strategy behind pharma's lawsuits over drug pricing reform

explore

Why psychiatrists like me stop taking insurance

In areas with more Black doctors, Black people live longer

What is the Wagner Group? The 'brutal' Russian military unit in Ukraine

New guidelines on severe brain injury complicate already difficult decisions

Obesity experts on risks of Wegovy, Ozempic weight loss drugs

JPM 2024 Day 3: Biotech Updates from Verve, Roivant, etc

focus

knowledge

Wikipedia

hotspot